by Sarah Avery, Duke University Graphical abstract. Credit: Cell (2024). DOI: 10.1016/j.cell.2023.12.002The path to a successful HIV vaccine depends on a critical first step—activating specific immune cells that induce broadly neutralizing antibodies. Reporting Jan. 4 in the journal Cell, a research team led by the Duke Human Vaccine Institute has achieved that requisite initial step in...
by Fred Hutchinson Cancer Center Credit: Unsplash/CC0 Public Domain Researchers from Fred Hutchinson Cancer Center in Seattle, Scripps Research in La Jolla, California, IAVI and other collaborating institutions have characterized robust T-cell responses in volunteers participating in the IAVI G001 Phase 1 clinical trial to test the safety and immune response of a self-assembling nanoparticle HIV vaccine. Their work, published in Science...
by The Scripps Research Institute A structural depiction of two HIV nanoparticle vaccines (E2p and I3-01v9) and a close-up of the Env proteins these nanoparticles display on their surfaces (HIV-1 BG505 UFO trimer). The vaccines are designed to have shorter sugars (or glycans) on the Env protein. Credit: Scripps Research A new HIV vaccine from Scripps Research has shown a significantly...
by The Wistar Institute The Wistar Institute’s Dr. Dan Kulp. Credit: The Wistar Institute Nearly four decades after its discovery, HIV has killed 36.3 million people, with no vaccine in sight. However, a new study by researchers at The Wistar Institute, an international biomedical research leader in cancer, immunology, infectious disease, and vaccine development, takes...
by NIH/National Institute of Allergy and Infectious Diseases Scanning electromicrograph of an HIV-infected H9 T cell. Credit: NIAID An experimental HIV vaccine based on mRNA—the same platform technology used in two highly effective COVID-19 vaccines—shows promise in mice and non-human primates, according to scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part...
by Sheikh Abdul Rahman, Bhrugu Yagnik, Rama Rao Amara, The Conversation Credit: Pixabay/CC0 Public Domain A new combination treatment for HIV can strengthen a patient’s immune response against the virus even after they stop taking traditional medications, according to a study published in the journal Science Immunology we co-led at the Amara Lab at Emory Univeristy. People with HIV take...
by The Scripps Research Institute A computer image of HIV’s outermost layer, densely coated with sugar molecules (purple) that do not trigger an immune response. Most of the surface not covered in sugars (in red and yellow) is highly variable, making it difficult for the immune system to generate antibodies capable of neutralizing the virus. Credit: Sergey Menis,...
HIV infecting a human cell. Scientists at The Scripps Research Institute (TSRI) have made a discovery that could speed efforts to develop a successful HIV vaccine. The scientists found that on the HIV envelope protein, at a site important for viral function, a small group of sugar molecules, known as glycans, serves as a...
